• CNS Pharmaceuticals holds the exclusive worldwide license to the Berubicin chemical compound
• Berubicin is CNSP’s lead, novel anthracycline candidate for the treatment of glioblastoma multiforme (“GBM”) that was the subject of a previously conducted Phase 1 clinical trial, which had a clinical benefit response rate of 44%
• CNSP has sublicensed Berubicin to WPD Pharmaceuticals in 31 countries primarily in eastern Europe and western Asia
• WPD plans to conduct a Phase 2 trial in adults with GBM and a Phase 1 trial for pediatric patients with malignant gliomas
• CNSP intends to conduct its own Phase 2, potentially pivotal, trial in s GBM patients who have failed first-line therapy and is on track to commence the study in March 2021
• Both WPD and CNSP have received favorable opinions for their respective protocols to be used in their clinical trials

The Lower Silesian Medical Chamber Ethics Committee in Wroclaw, Poland recently gave WPD Pharmaceuticals (CSE: WBIO) (Frankfurt: 8SV1) (“WPD”), CNS Pharmaceuticals, Inc.’s (NASDAQ: CNSP) sublicensee in Europe and Asia for Berubicin, a positive opinion for its WPD-201 Clinical Trial Protocol to be used in the planned forthcoming Berubicin clinical trial in adults with glioblastoma multiforme (“GBM”).

Notably, a regulatory body within a given territory – in this case, Poland – shares a positive opinion to ascertain that a study, through its protocol, respects participants’ dignity, rights, safety, and well-being.

This new development, which CNSP and WPD announced in a news release recently, set the wheels in motion for the eventual approval of WPD’s studies – a multicenter Berubicin Phase 2 adult GBM trial and a multicenter pediatric Phase 1 malignant glioma trial.

“This is an important step for WPD,” commented Mariusz Olejniczak, WPD’s CEO (https://ibn.fm/PH9lC). “From both a project and sublicense agreement point of view. After receiving the Central Ethics Committee’s positive opinion, we are planning to submit our application to the Office for Registration of Medical Products, Medical Devices, and Biocidal Products, which is the Polish equivalent of the FDA. We hope to receive an approval within three months from submission.”

WPD plans to start the Phase 2 trial in the first half of 2021 and the Phase 1 trial later in 2021. This will bring the total number of Berubicin clinical trials to be started in 2021 to three as CNSP will also conduct its Phase 2 trial. CNSP’s Phase 2 trial will evaluate the efficiency and safety of Berubicin as a treatment for adults with GBM who have failed first-line therapy.

CNSP slated its study for March= 2021, having received approval from the U.S. Food and Drug Administration (“FDA”) for its Investigational New Drug (“IND”) application and a study level Central IRB approval from the Central IRB for the CNS-201 Clinical Trial Protocol.

“We are pleased for WPD to achieve this key milestone and are encouraged by their continued execution in furthering the development of Berubicin,” John Climaco, the CEO of CNS Pharmaceuticals, said. “We look forward to continuing our trial preparations, as well as WPD’s planned submissions to the Polish Competent Authority”.

Berubicin is CNSP’s novel anthracycline (a chemotherapy drug), which is notably unique from other anthracyclines. Historically, anthracyclines have never been used to treat primary or metastatic brain cancers because they did not have any demonstratable ability to cross the blood-brain barrier and achieve significant levels of activity in the brain. However, based on limited available data, it appears that Berubicin can cross the barrier (https://ibn.fm/JHtMJ).

Its efficacy was demonstrated in Phase 1 clinical trial completed in 2006 by Reata Pharmaceuticals, Inc. – CNSP has since acquired all the data from this trial and is currently the exclusive Berubicin license holder, subject to the sublicense agreement with WPD. The Phase 1 trial, which has 25 participants evaluable, had an overall response rate (clinical benefit of stable disease or better) of 44%. Notably, one patient’s experience with the treatment was durable as they have remained cancer-free for well over a decade through the most recent clinical evaluation on November 6, 2020. The Phase 1 trial had a limited sample size, so there can be no guarantee that similar results will be realized in the subsequent trials, but it is promising. CNSP’s Phase 2 trial will have an estimated enrollment of over 200 participants (https://ibn.fm/C6426).

CNSP is a clinical-stage biotechnology company that focuses on developing new treatments for the brain and central nervous system’s primary and metastatic cancers. Berubicin, the Company’s lead anthracycline drug candidate, is a promising treatment for glioblastoma multiforme (GBM). WPD is a biotechnology company that focuses on researching and developing medicinal products involving biological compounds and small molecules in the oncology and virology fields. WPD holds a Berubicin sublicense for the European and Asian markets.

For more information, visit the company’s website at www.CNSPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Telehealth sector going through explosive growth; patients’ data protection remains key challenge
• Although relaxed due to COVID-19 outbreak, HIPAA guidelines protecting patients’ data security, privacy likely to tighten as pandemic abates
• RYAH appears ready to respond to strict data security requirements, uses medical data in a HIPAA-compliant setting

Telehealth is becoming increasingly popular with patients and doctors alike, but securing the integrity of patient information remains critical. As a company developing proprietary technology supporting a data-driven healthcare approach, RYAH Group appears ready to respond to the strict data security requirements.

With patients needing more access to health care, and providers and payers looking to reduce health-care costs, the use of telehealth solutions is exploding. More and more medical staff and patients alike are embracing digital healthcare options as a replacement for in-person care. Although the pandemic fuels the recent surge, the overall growth is not likely to stop once the pandemic tails off. For example, the global telemedicine market is expected to exceed $130.5 billion by 2025, with the U.S. telemedicine market expected to surpass $64.1 billion by 2025 (https://ibn.fm/AVY0p).

The technologies that power telemedicine growth are big data analytics and cloud computing. The enormous amount of data generated by devices such as smartphones, monitoring technologies, wearables and online video conferencing has opened up a world of opportunities that allows information sharing and superior analytics. Only two barriers impede the widespread adoption of big data and cloud computing in telemedicine: data privacy and security. If these critical aspects are addressed, the power of the novel technology can be harnessed to its true potential (https://ibn.fm/YRVm3).

Both patients and medical professionals are becoming accustomed to communicating through electronic devices. Although telehealth brings immense benefits, especially during the pandemic, it creates risks that must be addressed. For example, it opens up opportunities for patients’ information to fall into the wrong hands, either by accidental or malicious intent. Transmitting protected health information through unencrypted, unsecured platforms may expose protected health information.

The Health Insurance Portability and Accountability Act of 1996 (HIPAA) is the U.S. legislation designed to ensure that medical providers provide data privacy and security provisions for safeguarding their patient’s medical data. Although HIPAA guidelines are temporarily relaxed during the pandemic, this flexibility is not likely to remain as the pandemic subsides. Therefore, it is critical for health-care providers to use secure, HIPAA-compliant digital infrastructure to protect both themselves and patients at risk.

Unified data management is critical to ensuring that the right users have access to the right health-care data at the right time and in the right format. It allows health-care providers to have meaningful use of their data assets. Integrated data management, along with a formal data governance program, ensures data quality and trust in the data integrity.

As a company focused on the use of health devices, RYAH and its business model is founded on data and data management. RYAH leverages HIPAA-compliant medical data, fueling complex artificial intelligence algorithms to empower personalized treatment plans based on collective information.

For more information, visit the company’s website at www.RYAHGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to RYAH Group are available in the company’s newsroom at https://ibn.fm/RYAH

• Medical College of Georgia research shows beneficial effects from use of CBD oil to treat COVID-19 symptoms
• CBD oil found to increase apelin levels in the human body, a key peptide needed to reduce lung inflammation resulting from COVID-19
• PacRoots Cannabis specializes in developing premium quality strains, including plants with high CBD content, rare terpene contents, which could potentially be used for medicinal purposes

Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) has developed a strong reputation within the global cannabis sector for producing premium quality strains and products through the employment of a meticulous, genetics-focused approach towards harvesting its crops. Following a remarkable study into the potential beneficial effects of CBD oil, the Canada-based cannabis manufacturer may potentially find itself at the forefront in the development of a remedial drug in the battle against COVID-19 (https://ibn.fm/BE8y1). Cytokine, a type of protein secreted by immune cells in response to inflammation and infection, has been found to regulate the maturation, growth, and responsiveness of particular cell populations – thereby playing an important role in the human body’s immune systems. However, an overactive cytokine response resulting from a potentially acute case of COVID-19 could also result in severe patient lung damage and, in certain cases, even lead to death. Researchers have found that a naturally occurring peptide called Apeline, which is traditionally produced in the heart, lungs, brain and blood and works as a key regulator in helping to normalize blood pressure and inflammation within the human body, may act as a suitable foil to cytokine. A recently published study carried out by scientists at the Medical College of Georgia and Dental College of Georgia (https://ibn.fm/QxEg9) found that CBD oil was shown to habitually increase apelin levels, in addition to improving blood oxygen content and reducing inflammation – and thus, the lung damage incurred through cytokine activity. In the study, scientists investigated a disease called adult respiratory distress syndrome (“ARDS”), the effects of which can result in similar lung tissue damage to that seen in severe COVID-19 cases. In the studies, blood levels of apelin were found to drop to almost zero in the midst of the disease but increased nearly twenty-fold when CBD was administered. “CBD almost brought it back to a normal level,” stated Dr Jack Yu from the Medical College of Georgia when elaborating on the effects of CBD usage on apelin levels present in the human bloodstream. While researchers were cautious on the study’s results given the need for further in-depth research into the field, it was evident that there was a strong existing correlation between ARDS and the role of apelin in reversing lung tissue damage, as well as the benefits of increasing apelin levels through CBS treatment (https://ibn.fm/IgBvn). Pac Roots Cannabis has been a pioneer within the cannabis sector in terms of improving and modifying the genetic make-up of their cannabis product, most recently through a strategic licensing agreement with Phenome Once Corp. The agreement granted Pac Roots access to one of Canada’s largest live genetic cannabis libraries with lab and field-tested, selectively bred seedlings. The Company has employed these to grow, breed and clone its own unique brands. The tie-up has enabled Pac Roots to offer its customers a remarkable portfolio of over 350 meticulously designed cultivars, including CBD-dominant plants possessing rare terpene profiles. Due to its specialty CBD plant offerings, Pac Roots appears well positioned to benefit from CBD’s positive effects on assuaging COVID-19 complications. For more information, visit the company’s website at www.PacRoots.ca. NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://ibn.fm/PACR

• Microcap stocks outperforming 2020 record highs, currently trading at 40% above 200-day moving average
• SRAX’s Sequire SaaS platform provides public companies with tools to monitor trading activity, provides actionable insights for use in marketing campaigns
• Sequire subscriber base surged to 3 million active traders across 90 public companies since its 2019 inception

Investor interest sent microcap stocks sky-high in 2020, a trend that is continuing well into 2021 with returns on some microcap ETFs surging at several times the rate of comparable large-cap ETFs (https://ibn.fm/Bu86D). As the tide of investor interest continues to flow into microcaps, public companies are leveraging the power of data through Sequire, SRAX’s (NASDAQ: SRAX) investor analytics SaaS platform that unlocks data and insights critical to targeted marketing campaigns in order to engage current traders and attract new investors.

Small caps – companies generally valued between $50 and $300 million – are typically thought to be more volatile and riskier when compared to established companies. Throughout 2020 and so far in 2021, that risk has paid off for investors willing to take a chance on new companies – particularly those included by SRAX subsidiary LD Micro in its North American microcap index which comprises nearly 1200 companies over 14 sectors (https://ibn.fm/m58cx).

“I cannot believe what I’ve seen in the past year,” said LD Micro President Chris Lahiji. “The LD Micro Index has more than tripled from its March 2020 lows. The tiniest public companies were also some of the biggest winners last year, and already year-to-date.”

After surging 20% in 2020, the Russell 2000 continues to outperform its historic highs and is now trading at 40% above its 200-day moving average as retail traders flood the market amid low interest rates and increased fiscal stimulus. The resulting investor interest has left many public companies looking for insights into trading activity to facilitate communications and gauge investor sentiment.

Sequire provides clarity for public companies via access to tools which help them monitor shareholder buying and selling activity while tracking key investors and outstanding warrants. The service also features applications that allow subscribers to publish company-specific news and obtain stakeholder opinions through customized surveys. The platform has experienced staggering growth since its 2019 inception to include over 3 million active retail investors across 90+ public companies (https://ibn.fm/sPoOj).

“We have been discussing the importance of retail investors in public companies since the inception of Sequire,” said SRAX CEO and Founder Christopher Miglino. “It’s the very reason why we built the platform and related tools – to help companies effectively communicate with these investors.”

As the importance of data increases across the digital landscape, SRAX maintains its commitment to build the largest and most reliable opted-in data sets across a broad range of industry verticals. Through its specialized suite of applications and tools, the Company focuses on providing brands and companies across the CPG, luxury, lifestyle and financial spaces with high-quality data that provides critical, actionable insights integral to strategic marketing campaigns.

For more information, visit the company’s website at www.SRAX.com.

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• Adelia Therapeutics has achieved earn-out milestones outlined in contribution agreement with Cybin
• Adelia ideal acquisition for Cybin, as it leads innovation in researching psychedelic treatment options in the mental health space
• Acquisition results in Cybin obtaining extensive intellectual property portfolio and product pipeline

Cybin (NEO: CYBN) (OTC: CLXPF), a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions, has announced that its recently acquired subsidiary, Adelia Therapeutics Inc., has achieved the earn-out milestones outlined for the time period in the contribution agreement between the two companies (https://ibn.fm/c6o2E). That milestone includes the successful synthesis of multiple tryptamine derivatives.

Furthermore, the synthesis of tryptamine derivatives resulted in quantities adequate enough that Adelia could initiate in vitro “Proof of Principle”; establish that an ADME/PK has been completed; and demonstrate “In Vitro” ADME “Proof of Principle” that specific synthesis modifies the metabolism of a psychedelic tryptamine.

Adelia focuses on developing medicinal psychedelics with improved dosing efficacy and therapeutic indices to address unmet medical needs, which makes the company an idea fit for Cybin, as it leads the way in researching psychedelic treatment options in the mental health space. Adelia’s proprietary development strategy is based on chemical modifications to already known tryptamine derivatives that significantly alter the pharmacokinetic properties of those derivatives without changing their therapeutic potential. The company’s recent milestone is a direct result of this focus and its dedication to seeking to minimize inter-patient variability by better controlling drug metabolism without loss of efficacy.

Cybin’s acquisition of Adelia resulted in Cybin obtaining an extensive intellectual property portfolio and product pipeline that could lead to diversification beyond major depressive disorder (“MDD”) treatments and regimens. Adelia’s three-pillar development strategy includes novel therapeutics, delivery methods and therapeutic regimens focused on improving patient outcomes. The acquisition also results in Cybin gaining psychedelic derivative drug-development candidates, with the first lead compounds expected to enter clinical studies in 2021.

“We are thrilled to join forces with Adelia,” said Cybin CEO Doug Drysdale when announcing the acquisition (https://ibn.fm/T5eIg). “We see this acquisition as potentially advancing Cybin’s ability to innovate our psychedelic drug development program and diversify beyond major depressive disorder. Adelia’s focuses on novel delivery methods and innovative therapies may contribute to our goal of therapies with faster onset of action, smoother pharmacokinetic profiles, shorter treatment periods, and reduced side effects. Adelia’s expertise across multiple molecules and multiple indications, could potentially give Cybin the ability to address gaps across a larger domain.”

The Adelia acquisition also combines two talented teams that share strong patient-first values and track records of innovation in the field of psychedelics. Adelia’s leadership team of accomplished scientists brings invaluable preclinical development experience that complements Cybin’s clinical experience and resources.

Cybin is a life sciences company advancing psychedelic therapeutics for various psychiatric and neurological conditions. Cybin is developing technologies and delivery systems, aiming to improve bioavailability, to potentially achieve the desired medicinal effects of psychedelics at low dosage levels. The new delivery systems are expected to be studied through clinical trials to confirm safety and efficacy.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• BRSF working to improve diagnostics by leveraging AI and machine learning
• Cloud-based infrastructure, AI-assisted diagnostic analysis is in development phase
• Brain Scientific creating long-term monitoring capabilities that leads to collection of essential biomarkers

Brain Scientific (OTCQB: BRSF), a commercial-stage, health-care company focused on developing innovative and proprietary medical devices and software, is working on developing state-of-the-art AI diagnostic analytics. The company’s two FDA-cleared products — the NeuroCap(TM) and NeuroEEG(TM) — offer cost-effective disposable alternatives to existing electroencephalogram (“EEG”) solutions. These disposable and simple-to-use devices allow medical professionals to collect necessary diagnostic information quickly.

But BRSF isn’t stopping there.

The company’s goal is to further improve diagnostics by leveraging artificial intelligence (“AI”) and machine learning processes to analyze a database of brain readings to improve diagnosis and treatment of neurological conditions.

The company is using in-house development in order to provide diagnostic interpretation assistance for health-care providers. Currently, a secure cloud-based infrastructure and AI-assisted diagnostic analysis are in the development phase.

BRSF’s remote diagnostic devices that are already in active use will be used to acquire large datasets of neurological information that will be uploaded to the company’s secure cloud technology. These neural networks of data will be used to identify patterns and biomarkers for neurological disease in the near future. Eventually, this data will be integrated with external graph datasets that contain neurological clinical and research data. When that happens, the neural networks will comb the data to detect patterns. Over time the AI will be able to make predictions that will aid neurologists and increase access to complex neuro-diagnostic expertise (https://ibn.fm/3V7Wx).

As more clinical trials and studies are done on neurological conditions, additional data is acquired. On the Neuroscience Information Framework (“NIF”), there are currently over 4,000 databases of neurological information (https://ibn.fm/7pKza). No single neurologist can attempt to evaluate that much data to discover the best treatment for the one patient under their care.

But a computer can. By creating a secure cloud of BRSF’s data that can be integrated with external datasets and using AI with machine learning to filter through the data, neurologists will be able to locate the information needed to best help their patients. The implications of this technology is huge.

An article in Forbes states that “Biomarkers of Longevity integrated with AI and machine learning techniques have the potential to help prevent age-related diseases and extend health span,” reported a “Forbes” artice (https://ibn.fm/s5MWM). “Advances in the development of biomarkers will allow doctors to assess health, quantify the effect of interventions, and produce personalized medical reports.”

Big data plus AI will make neurological care accessible in a way it has not yet been, and BRSF committed to help pave the way.

To learn more about this company, visit www.BrainScientific.com/Invest-Now.

NOTE TO INVESTORS: The latest news and updates relating to BRSF are available in the company’s newsroom at https://ibn.fm/BRSF

• Asia Broadband Inc. is focused on the production, supply and sale of precious and base metals, primarily to Asian markets
• The company recently acquired a high potential mineral property in the state of Colima, Mexico
• Asia Broadband has teamed with crypto wallet creator Core State Holdings Corp. to develop the AABB Gold token, a gold-backed cryptocurrency coin
• On February 25, 2021, Asia Broadband announced management and board approval of a stock dividend for shareholders

Asia Broadband (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets. The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space. Development Program in Colima, Mexico In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property. The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production. Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply. AABB Gold Token In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain. In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.” Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token. AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia. For more information, visit the company’s website at www.AsiaBroadbandInc.com. NOTE TO INVESTORS: The latest news and updates relating to AABB are available in the company’s newsroom at https://ibn.fm/AABB

• Archaic technology contributes to dismal recurrence rate in bladder cancer
• Imagin Medical revolutionizes the way surgeons can visualize cancer to better identify, and remove during surgery
• There is potential to extend this technology to virtually other endoscopic procedures

The battle against cancer is too often set back by crushing blows of recurrence. The disease is insidious. If every single malignant cell of a tumor is not completely removed, it can rebound and attack again. Nowhere is this dismal recurrence more prevalent than in bladder cancer. Caught early, bladder cancer stands a better chance of being successfully treated through surgery and therapeutics. However, bladder cancer has the highest recurrence rate of all cancers. 50% of bladder cancers recur, attacking anew from a just few cells that were missed during surgery. Surgeons do the best they can, but with outdated technology they can’t clearly visualize inside the bladder, clearly identify and then remove potentially malignant cells. This dilemma is about to be rectified with a breakthrough new technology that, will gives surgeons, not only the ability to clearly see inside the bladder, but also more easily identify and surgically remove all the cancer

With bladder cancer as its first target, surgical imaging company Imagin Medical (CSE: IME) (OTCQB: IMEXF) intends to change the dismal outcomes of bladder cancer recurrence with its i/Blue Imaging(TM) System. The company’s patented, ultrasensitive imaging technology aims to revolutionize the archaic techniques currently used in treating bladder cancer and extend the technology to multiple other surgical procedures.

Conventional diagnostic procedures for visualizing bladder cancer during surgery allow surgeons to see inside the body with a thin, lighted, flexible tube which uses white light to illuminate the bladder. White light images show a full picture of the bladder but do not effectively highlight cancerous cells which can be left behind to attack again. A recent advancement uses blue-filtered white light to better detect tumors and cancerous cells not seen with white light. However, surgeons cannot use blue light images to operate. Blue cystoscope images aren’t in real time and the position in the bladder can be confusing, requiring the surgeon to manually switchback and forth from white to blue light images These technologies remain lacking and recurrence remains at high levels. 600,000 people live in fear that their cancer will return, unfortunately about half of them will have their worst fears realized.

Imagin Medical’s i/Blue Imaging System rectifies the limitations of white and blue light cystoscopies. Combining both the white and blue light with an FDA approved imaging agent, the i/Blue System displays side-by-side images in real-time, eliminating the need to switch back and forth between the two images. Using the i/Blue System, surgeons can now see the full landscape of the bladder and identify malignant cells in a single, unified process. This technological advancement is expected to drive down the dismal recurrence of bladder cancers and deliver hope to the tens of thousands that suffer with the disease.

Imagin Medical’s unique i/Blue Imaging System can attach to virtually any endoscope model currently in use which creates a plug and play system adaptable to almost any clinical setting which opens vast new markets for the company’s technology. The FDA approval process is underway, and the company’s intellectual property is well-protected.

Imagin Medical has reimagined technology to create better outcomes for cancer patients, and as the technology gains traction it may well become the new standard of care for bladder cancer and other endoscopic procedures.

For more information, visit the company’s website at www.ImaginMedical.com.

NOTE TO INVESTORS: The latest news and updates relating to IMEXF are available in the company’s newsroom at https://ibn.fm/IMEXF

• Holding company Clean Power Capital Corp.’s investee PowerTap, a hydrogen fueling innovator, has teamed with carbon energy credits expert Carbonomics to develop and maximize the company’s ability to use clean energy credits
• PowerTap is driven to establish a “hydrogen highway” for environmentally conscious motorists looking for an effective alternative fuel
• Clean Power Capital is a majority investor in PowerTap — a key part of Clean Power’s focus on building up health and renewable energy enterprises
• PowerTap’s next-generation hydrogen stations are also capable of generating electricity to help them continue to pump fuel during a power outage or even potentially power the entire gas stop operation where the fuel stations are located

Holding company Clean Power Capital (CSE: MOVE) (FWB: 2K6) (OTC: MOTNF) advanced its mission of helping health and renewable energy enterprises achieve their growth potential when it became a majority investor in California’s PowerTap Hydrogen Fueling Corp last fall. PowerTap has proven to be a formidable innovator in the clean power industry through its recent agreements with the Andretti Group for fuel station location, marketing and leadership (https://ibn.fm/lF640). Now PowerTap is maximizing its ability to navigate the regulatory hurdles for obtaining certification and emission reduction credits in the United States and international markets by teaming up with Carbonomics, and expert in the process of monetizing carbon credits. “Carbon credits are a key part of every clean energy company’s strategy, and we are pleased to partner with Carbonomics to leverage their expertise and experience to maximize carbon credit revenues,” stated PowerTap CEO Raghu Kilambi (https://ibn.fm/UUvfG). “Leading clean energy companies like Tesla have used emission-reduction credit revenues (https://ibn.fm/K8cBV) to accelerate their growth and cash flow.” PowerTap is preparing to install its 1,250-kilogram hydrogen production and dispensing stations at some of the Andretti Group’s more than 100 retail chain stores, which are focused on fuel, convenience and food operations through facilities under the Chevron, Texaco, Shell, 76, Circle K, Pacific Pride and CFN and other brands. The stations are noteworthy not only for their role in helping to build up a “hydrogen highway” throughout California and eventually into other parts of the country, but also because they are capable of generating electricity. “While much less electricity is needed to produce blue hydrogen vs green hydrogen (https://ibn.fm/39Un2), PowerTap recognized that electricity shortages may affect the operation of its fueling stations,” the company stated in a recent news release acknowledging the power outages in Texas brought on by unusual freezing weather (https://ibn.fm/D9Bd3). “To address this potential issue, PowerTap’s 3rd Generation Onsite Hydrogen fueling unit will have an industrial hydrogen fuel cell that can be used to turn excess hydrogen into electricity that can be used in various capacities including powering further hydrogen production or the rest of the gas/truck stop operations.” PowerTap is a key part of Clean Power Capital’s investment portfolio. Clean Power’s investment mandate is focused on high return investment opportunities, the ability to achieve a reasonable rate of capital appreciation and to seek liquidity in its investments. For more information, visit the company’s website at www.CleanPower.Capital. NOTE TO INVESTORS: The latest news and updates relating to MOTNF are available in the company’s newsroom at https://ibn.fm/MOTNF

• PlantX Life welcomes new brand ambassadors Venus Williams and Alicia Silverstone
• Plant-based lifestyle allowed Williams to “continue her dreams” as a world-renowned tennis player
• Silverstone chose plant-based two decades ago, calling it “just a healthier way to be”

PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) has announced world-renowned tennis player Venus Williams and well-known actress Alicia Silverstone as brand ambassadors for the company — a company that Williams noted is “long overdue.” “I can’t tell you how excited I am to be involved, an ambassador, a cheerleader, a stakeholder, and all the above, in PlantX,” said Williams following the announcement, which was made during the company’s annual general meeting (https://ibn.fm/lVSOG). “It’s the first market of its kind, and it’s long overdue.” A former number 1-ranked tennis player with four Olympic gold medals and seven Grand Slam singles titles to her name, Williams first became involved in a plant-based lifestyle 10 years ago when she was diagnosed with an autoimmune disease that threatened to derail her tennis career. At the suggestion of her sister Serena, also a world champion tennis player, Williams committed to a three-week, all-raw vegan program and saw immediate results. “That was my introduction,” she said. “Not only did I learn a lot about food but the food system, and how it fills your body and how we have strayed so far away from where we started as humans and to where we are right now.” Williams noted that a plant-based lifestyle has “become my passion and my hobby, and it’s been able to help me not only get back on tour but also to live a much better quality of life, because when you have a chronic illness, your quality of life goes down. To be able to live a much better quality of life was obviously the first step, and then to be able to continue to live my dreams was the second step.” Silverstone noted similar health benefits when she adopted her vegan lifestyle 20 years ago before many people were even familiar with it, she said, speaking about her enthusiasm for PlantX and her role as a brand ambassador for the Company. Although her primary motivation for choosing a plant-based diet was because she loved animals, she suffered from allergies and wanted to lose weight. “I took on this new way of eating, and I ditched all of that,” she said. “My asthma inhaler went away, my allergy shots went away, my body started to slim down, and this was all by accident. I just did it because I didn’t want to be mean to my dog anymore. . . I made the change but all these amazing health things began to happen. As I did research and started to look at all these studies, it just shows [plant-based] is just a healthier way to be.” Since her decision, Silverstone has become an outspoken advocate for health and wellness, with a particular interest in and support for the plant-based lifestyle. Silverstone and Williams have high praise for PlantX Life, a company that is pioneering its path in the plant-based space. As the digital face of the plant-based community, PlantX’s platform is the one-stop shop for everything plant-based. With its fast-growing category verticals, the Company offers customers across North America more than 10,000 plant-based products. In addition to offering meal and indoor plant deliveries, PlantX currently has plans to expand its product lines to include cosmetics, clothing and its own water brand. In addition, the Company uses its digital platform to build a community of like-minded consumers and to provide education. Its successful enterprise is being built and fortified through partnerships with top nutritionists, chefs and brands. For example, the company offers 20 unique pre-made meals designed by top chefs and nutritionists. These healthy meals are offered at extremely competitive prices with fast shipping and round-the-clock convenience. The Company’s commitment to customer service is the driving force behind its e-commerce platform, with innovative thinking driving its operation; the PlantX team is constantly envisioning new ways to collaborate with local restaurateurs and entrepreneurs to bring PlantX to the world. PlantX is committed to eliminating the barriers to entry for anyone interested in living a plant-based lifestyle and thriving in a longer, healthier and happier life. For more information, visit www.PlantX.com, www.PlantX.ca and www.Investor.PlantX.com and view the PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF